Research Progress on Roxadustat in the Treatment of Renal Anemia

近年来，肾性贫血的治疗取得了重大进展。罗沙司他作为全球首个获批的缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)，可模拟缺氧状态以稳定HIF-α亚基，从而激活内源性促红细胞生成素(EPO)的合成，并改善铁代谢。这为肾性贫血提供了一种全新的治疗策略。然而，其长期安全性以及HIF通路多靶点效应的潜在影响仍有待进一步验证。本综述旨在探讨罗沙司他治疗肾性贫血的作用机制、临床证据及其他潜在影响，从而为优化贫血管理提供见解。In recent years, substantial advancements have been achieved in the treatment of renal anemia. Roxadustat, as the world’s first approved hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mimics hypoxic conditions to stabilize HIF-α subunits, thereby activating endogenous erythropoietin (EPO) synthesis and enhancing iron metabolism. This provides a novel therapeutic strategy for anemia associated with chronic kidney disease (CKD). However, further validation is required regarding its long-term safety and the potential implications of the multi-target effects of the HIF pathway. This review aims to examine the mechanism of action, clinical evidence, and other potential effects of Roxadustat in treating anemia, thereby offering insights for optimizing anemia management.